Full Text View
Tabular View
No Study Results Posted
Related Studies
Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2 (GLP)
This study is not yet open for participant recruitment.
Study NCT00473733   Information provided by Assaf-Harofeh Medical Center
First Received: May 13, 2007   Last Updated: May 14, 2007   History of Changes

May 13, 2007
May 14, 2007
 
 
 
 
Complete list of historical versions of study NCT00473733 on ClinicalTrials.gov Archive Site
 
 
 
Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2
 

Glucagon like peptides receptors expression in the stomach of diabetes type 2 Glucagon like peptides (GLP-1, GLP-2), are hormones secreted by L cells located along the gastrointestinal tract. These hormones are secreted after meals and have some roles in regulating the digestion process, absorption, and sending signals to the brain that regulate food consumption. GLP peptides affect peripheral targets and have an important homeostatic role. GLP-1 decreases the circulatory glucose level and GLP-2 has trophic effects which enable adequate intestine growth.

We aimed in our study to investigate the GLP-1 and GLP-2 receptor expression in different zones of the stomach in diabetes type 2 patients. If there are differences, it might explain the pathological gastric emptying in these patients.

Understanding the function of these peptides may lead to new therapeutic options for diabetic patients with delayed gastric emptying.

Methods: 20 diabetes type 2 patients with symptoms that need upper endoscopy will be included in the study and 20 controls aged 18-70 years. Patients with neurological disease will be excluded. During esophagogastroduodenoscopy 3 biopsies will be taken from the antrum, corpus and cardia. The biopsies will be stored in -70. After RNA extraction the GLP receptors expression will established by real time PCR method. Patients with different expression compared to control will undergo isotopic scan for gastric emptying.

 
Phase IV
Interventional
Diagnostic, Non-Randomized, Open Label, Active Control, Crossover Assignment
Diabetes Mellitus Type 2
  • Procedure: GLP receptors expression
  • Procedure: ESOPHAGOGASTRODUODENOSCOPY
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Not yet recruiting
 
 
 

Inclusion Criteria:

  • 20 diabetes type 2 patients with symptoms that need upper endoscopy will be included in the study and 20 controls aged 18-70 years

Exclusion Criteria:

  • Patients with neurological disease will be excluded
Both
18 Years to 70 Years
No
Contact: Efrat Broide, MD 972-8-9779722 efibroide@yahoo.com
Israel
 
NCT00473733
 
65/07
Assaf-Harofeh Medical Center
 
Principal Investigator: Efrat Broide, MD Ethic committee of Asaaf Harofeh Medical Center
Assaf-Harofeh Medical Center
April 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP